Skip to main content

Table 3 Univariate and multivariate analysis of prognostic factors of OS

From: Clinicopathological features, treatment patterns, and prognosis of squamous cell carcinoma of the breast: an NCDB analysis

Variables

Univariate analysis

Multivariate analysis

HR(95%CI)

P

HR(95%CI)

P

Age

  < =50

1

 

1

 

 50–60

1.13 (0.89–1.44)

0.301

1.10 (0.86–1.40)

0.445

  > 60

2.25 (1.86–2.74)

< 0.001

2.11 (1.72–2.60)

< 0.001

Race

 White

1

 

1

 

 African American

1.51 (1.26–1.80)

< 0.001

1.05 (0.87–1.27)

0.576

 Others

0.43 (0.24–0.77)

0.004

0.48 (0.27–0.85)

0.012

 Unknown

0.53 (0.24–1.19)

0.126

0.49 (0.22–1.10)

0.082

Comorbidity score

 Score 0

1

 

1

 

 Score 1

2.17 (1.85–2.54)

< 0.001

1.65 (1.40–1.95)

< 0.001

Grade

 I

1

 

1

 

 II

1.20 (0.94–1.54)

0.149

0.98 (0.76–1.26)

0.877

 III

2.05 (1.62–2.58)

< 0.001

1.35 (1.05–1.74)

0.02

 Unknown/IV

1.86 (1.39–2.49)

< 0.001

1.05 (0.77–1.42)

0.767

T-stage

 T0-T1

1

 

1

 

 T2

2.24 (1.86–2.69)

< 0.001

1.65 (1.35–2.03)

< 0.001

 T3–4

5.63 (4.60–6.90)

< 0.001

2.75 (2.14–3.55)

< 0.001

 Tx

1.25 (1.04–1.51)

0.017

0.62 (0.45–0.85)

0.003

N-stage

 N0

1

 

1

 

 N1

1.82 (1.49–2.22)

< 0.001

1.77 (1.43–2.18)

< 0.001

 N2–3

3.61 (2.90–4.49)

< 0.001

2.18 (1.69–2.83)

< 0.001

 Nx

1.12 (0.94–1.32)

0.197

0.95 (0.70–1.30)

0.764

M-stage

 M0

1

 

1

 

 M1

8.47 (6.42–11.17)

< 0.001

4.50 (3.29–6.16)

< 0.001

 Mx

2.04 (1.74–2.39)

< 0.001

1.90 (1.53–2.36)

< 0.001

Histology

 Infiltrating Ductal Carcinoma

1

 

1

 

 Squamous Cell Carcinoma

2.39 (2.06–2.77)

< 0.001

1.37 (1.15–1.64)

< 0.001

Lymphovascular invasiona

 Absence

1

 

Not included

 Presence

1.91 (1.37–2.67)

< 0.001

 Not applicable/Unknown

2.18 (1.63–2.91)

< 0.001

Estrogen Receptor

 Negative

1

 

1

 

 Positive

0.53 (0.46–0.61)

< 0.001

0.86 (0.67–1.10)

0.218

 Unknown

0.85 (0.67–1.08)

0.195

2.46 (0.60–10.15)

0.212

Progesterone Receptor

 Negative

1

 

1

 

 Positive

0.56 (0.48–0.65)

< 0.001

0.96 (0.76–1.20)

0.724

 Unknown

0.92 (0.73–1.16)

0.484

0.31 (0.08–1.27)

0.103

HER2a

 Negative

1

 

Not included

 Positive

0.83 (0.57–1.22)

0.347

 Borderline/Unknown

1.20 (0.87–1.66)

0.266

Surgery

 Breast-conserving surgery

1

 

1

 

 Mastectomy

2.22 (1.90–2.59)

< 0.001

1.26 (1.04–1.54)

0.02

 Others/Unknown

7.05 (5.77–8.62)

< 0.001

6.57 (5.04–8.55)

< 0.001

Radiation therapy

 No

1

 

1

 

 Yes

0.54 (0.47–0.62)

< 0.001

0.92 (0.77–1.10)

0.351

 Unknown

0.50 (0.24–1.05)

0.067

0.54 (0.25–1.17)

0.12

Chemotherapy

 No

1

 

1

 

 Yes

0.89 (0.77–1.03)

0.116

0.67 (0.55–0.80)

< 0.001

 Unknown

0.72 (0.53–0.99)

0.043

0.61 (0.43–0.85)

0.004

Endocrine therapy

 No

1

 

1

 

 Yes

0.44 (0.38–0.51)

< 0.001

0.60 (0.50–0.73)

< 0.001

 Unknown

0.56 (0.40–0.78)

< 0.001

0.77 (0.54–1.09)

0.145

  1. HR Hazard ratio, CI confidence interval
  2. aOnly patients diagnosed after 2010 were included